

**AstraZeneca – Call For Grant Applications
(CGA Respiratory AAAAI 2022 Severe Asthma Epithelial Cytokines Emerging Therapies 2021-06)**

Submission Deadline	Accepting applications until 9 am EST on August 16, 2021
Primary Area of Focus	Respiratory
Therapeutic Area	Severe asthma
Need	<p>Airway diseases are heterogeneous in nature, with inflammation resulting from complex interactions between airway structural cells and the innate/adaptive immune system.</p> <p>Specific epithelial cytokines (also referred to as alarmins, e.g. IL-25, IL-33, and TSLP) have been identified as upstream mediators/triggers of the inflammatory response in asthma as well as other airway diseases, and there is clinical trial data supporting their potential role in the treatment of severe asthma.</p> <p>Allergists and clinical immunologists who manage patients with airways disease should be aware of the roles that epithelial cytokines may play in airway disease pathophysiology and clinical data that provides evidence for their potential relevance in the future treatment of severe asthma.</p>
Educational Program	Consisting of, but not limited to, a live non-CME Educational Program held at the AAAAI annual meeting, as well as a subsequent accredited activity enduring the content to broader audience.
Budget	≤ \$330,000.00
Successful submission	<ul style="list-style-type: none"> • Independently-developed application, providing rationale for and detailed description of the goals, learning objectives, educational strategy, format, execution and measurement of program • Proposed activities will: <ul style="list-style-type: none"> ○ build upon content included in previously-executed programs and that in activities presently available ○ leverage the latest digital technologies for learner engagement, including multimedia elements and learner interactivity with faculty and content ○ employ educational strategies for maximal retention and application of content by tailoring to the specific needs of and learning styles of the proposed audience ○ include a synchronous live stream • Meaningful outcomes from previously executed program with similar goal and format • Ability to achieve Level 4 outcomes, report monthly metrics / quarterly outcomes (broken down by specialty, profession and geography)
CGA Code	AAAAI 2022 Severe Asthma Epithelial Cytokines Emerging Therapies 2021-06
Website URL	https://www.astrazenecagrants.com/us-grants.html

Program Requirements:

The Program must be planned and executed as an accredited activity and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and, if applicable, accreditation standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.